A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.

NCT00272701 Phase 4 COMPLETED

The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation of esomeprazole 40 mg compared to pre-study PPI treatment.

Details

Lead sponsor	AstraZeneca
Phase	Phase 4
Status	COMPLETED
Enrolment	450
Start date	2005-12
Completion	2007-02

Conditions

• Gastroesophageal Reflux Disease

Interventions

• Esomeprazole
• Other PPI marketed in Sweden

Primary outcomes

• The proportion of patients free from heartburn

Countries

Sweden